Share class: Evotec SE

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A1177,909,559159,960,144 ( 89.91 %) 215,000 ( 0.1208 %) 89.91 %

Major shareholders: Evotec SE

NameStocks%Valuation
Excalibur Luxco SARL
9.966 %
17,730,913 9.966 % 101 M €
MAK Capital One LLC
7.128 %
12,681,898 7.128 % 72 M €
Mubadala Investment Co. (Investment Company)
6.454 %
11,481,502 6.454 % 66 M €
Goldman Sachs Asset Management LP
5.652 %
10,055,638 5.652 % 57 M €
T. Rowe Price International Ltd.
4.568 %
8,127,117 4.568 % 46 M €
Black Creek Investment Management, Inc.
3.127 %
5,563,329 3.127 % 32 M €
Global Alpha Capital Management Ltd.
3.056 %
5,437,444 3.056 % 31 M €
Connor, Clark & Lunn Investment Management Ltd.
2.89 %
5,141,392 2.89 % 29 M €
LLB Invest Kapitalanlagegesellschaft mbH
0.1686 %
300,000 0.1686 % 2 M €
Paladin Asset Management Investmentaktiengesellschaft TGV
0.1686 %
300,000 0.1686 % 2 M €
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
NameStocks%Valuation
Mubadala Investment Co. (Investment Company)
5.169 %
4,597,701 5.169 % 13 M €
DCF Advisers LLC
1.198 %
1,065,274 1.198 % 3 M €
WCM Investment Management LLC
0.7052 %
627,260 0.7052 % 2 M €
0.5723 %
509,050 0.5723 % 1 M €
Optiver Holding BV
0.3188 %
283,576 0.3188 % 794 013 €
Morgan Stanley Capital Services LLC
0.292 %
259,744 0.292 % 727 283 €
LPL Financial LLC
0.1375 %
122,346 0.1375 % 342 569 €
Envestnet Asset Management, Inc.
0.1342 %
119,409 0.1342 % 334 345 €
Millennium Management LLC
0.1119 %
99,568 0.1119 % 278 790 €
Citadel Securities GP LLC
0.098 %
87,180 0.098 % 244 104 €
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░

Breakdown by shareholder type

Institutional37.25%
Others10.97%
ABC arbitrage SA0.29%
Individuals0.2%
Unknown51.29%

Based on 1000 largest holdings

Geographical origin of shareholders

United States
14.31%
Germany
10.59%
Canada
9.07%
United Arab Emirates
9.04%
United Kingdom
4.62%
France
0.42%
Individuals
0.2%
Austria
0.2%
Netherlands
0.16%
Luxembourg
0.05%
Spain
0.02%
Cayman Islands
0.01%
Ireland
0.01%
Denmark
0.01%

Based on 1000 largest holdings

Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
4,526